Title |
Infrequent mutation of ATBF1 in human breast cancer
|
---|---|
Published in |
Journal of Cancer Research and Clinical Oncology, August 2006
|
DOI | 10.1007/s00432-006-0148-y |
Pubmed ID | |
Authors |
Xiaodong Sun, Yingfa Zhou, Kristen B. Otto, Mingrong Wang, Ceshi Chen, Wei Zhou, Krithika Subramanian, Paula M. Vertino, Jin-Tang Dong |
Abstract |
Deletion at chromosome 16q is frequent in prostate and breast cancers, suggesting the existence of one or more tumor suppressor genes in 16q. Recently, the transcription factor ATBF1 at 16q22 was identified as a strong candidate tumor suppressor gene in prostate cancer, and loss of ATBF1 expression was associated with poorer prognosis in breast cancer. In the present study, we examined mutation, expression, and promoter methylation of ATBF1 in 32 breast cancer cell lines. Only 2 of the 32 cancer cell lines had mutations, although 18 nucleotide polymorphisms were detected. In addition, 24 of 32 (75%) cancer cell lines had reduced ATBF1 mRNA levels, yet promoter methylation was not involved in gene silencing. These findings suggest that ATBF1 plays a role in breast cancer through transcriptional downregulation rather than mutations. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 14 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 6 | 43% |
Student > Bachelor | 2 | 14% |
Other | 1 | 7% |
Student > Master | 1 | 7% |
Researcher | 1 | 7% |
Other | 2 | 14% |
Unknown | 1 | 7% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 6 | 43% |
Biochemistry, Genetics and Molecular Biology | 4 | 29% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
Medicine and Dentistry | 1 | 7% |
Unknown | 2 | 14% |